Immunovant, Inc. IMVT
Set alert
28.41 USD -0.76 -2.61%
At close · Nov 2
28.41 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
28.38 Day range 29.64
21.43 52-week range 45.42
- YTD
- +11.76%
- 1 year
- +15.11%
- Open
- 29.32
- Prev close
- 29.17
- Mkt cap
- 5.87B
- Vol
- 1.27M
- Avg vol
- 1.36M
- EPS
- -2.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 28.38
- High
- 29.64
- Forward P/E
- -10.33
- Beta
- 0.94
- Short ratio
- 10.91
- Inst. own
- 54.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 34.56
- 200-d avg
- 32.04
- 1y target
- 48.88
2Y chart
Events in this range
- Aug 11, 2025Earnings: -0.6; estimate -0.69; surprise 13.04%
- Nov 10, 2025Earnings: -0.73; estimate -0.72; surprise -1.39%
- Feb 6, 2026Earnings: -0.61; estimate -0.72; surprise 15.28%
- May 20, 2026Earnings: -0.73; estimate -0.59202; surprise -23.31%
- May 21, 2026Rating: HC Wainwright & Co. · Buy → Buy
- May 21, 2026Rating: B of A Securities · Buy → Buy
- May 22, 2026Rating: Truist Securities · Hold → Hold
- May 26, 2026Rating: Guggenheim · Buy → Buy
- Jun 30, 2026Rating: Citigroup · Buy → Buy
- Aug 4, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 6, 2026Earnings: -0.75; estimate -0.6289; surprise -19.26%
Signals (68)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| RSI: Overbought | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| RSI: Oversold | Mar 20, 2026 | 7 months ago |
| SMA: Bearish | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 5, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 17, 2026 | 8 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 11, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 12, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 11, 2025 | 11 months ago |
| RSI: Overbought | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 14, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 26, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 17, 2025 | 1 year ago |
| SMA: Bearish | Sep 12, 2025 | 1 year ago |
| SMA: Bullish | Sep 11, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Sep 4, 2025 | 1 year ago |
| SMA: Bullish | Sep 3, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 27, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 5, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 25, 2025 | 1 year ago |
| RSI: Overbought | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 26, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 4, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 18, 2025 | 1 year ago |
| RSI: Oversold | Feb 11, 2025 | 1 year ago |
| RSI: Oversold | Feb 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 17, 2025 | 1 year ago |
| RSI: Oversold | Jan 13, 2025 | 1 year ago |
Key statistics
- Market cap
- 5.87B
- Enterprise value
- 5.23B
- Trailing P/E
- 0.00
- Forward P/E
- -10.33
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 7.97
- EPS (TTM)
- -2.82
- Beta
- 0.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -238.70M
- Total cash
- 797.80M
- Total debt
- 0
- Return on equity
- -80.10%
- Shares outstanding
- 206.55M
- Short % of float
- 19.67%
- 50-day average
- 34.56
- 200-day average
- 32.04
Analyst view
Consensus: buy
Buy
Price target (mean) 48.88 +72.0% upside
Now 28.41
- Target (low)
- 30.00
- Target (mean)
- 48.88
- Target (high)
- 66.00
Ratings (0m) 17 13 buy · 4 hold · 0 sell
- Strong buy2
- Buy11
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.72212.
Financials — quick view
IMVT Revenue — quarterly 0
IMVT Net income — quarterly -153.22M
IMVT EPS — quarterly -0.75
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.73701 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.6289 | -0.75 | -0.12 | -19.26% |
| May 20, 2026 | Mar 31, 2026 | -0.59202 | -0.73 | -0.14 | -23.31% |
| Feb 6, 2026 | Dec 31, 2025 | -0.72 | -0.61 | +0.11 | +15.28% |
| Nov 10, 2025 | Sep 30, 2025 | -0.72 | -0.73 | -0.01 | -1.39% |
| Aug 11, 2025 | Jun 30, 2025 | -0.69 | -0.60 | +0.09 | +13.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 30, 2026 | Citigroup | main | Buy | Buy |
| May 26, 2026 | Guggenheim | main | Buy | Buy |
| May 22, 2026 | Truist Securities | main | Hold | Hold |
| May 21, 2026 | B of A Securities | main | Buy | Buy |
| May 21, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunovant.com
News
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
- Immunovant Q1 2027 Earnings Call: Complete Transcript
- Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
- Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
- IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
- IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
- Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
- Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
- Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Your note
Sign in to keep a note on IMVT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNETT EVA RENEE | Chief Financial Officer | Sale | Apr 15, 2025 | 396,774 |
| GEFFNER MICHAEL | Officer | Sale | Oct 21, 2025 | 217,958 |
| GIRÃO TIAGO M | Chief Financial Officer | Sale | Jul 22, 2026 | 240,798 |
| GLORIA MELANIE | Chief Operating Officer | Sale | Aug 19, 2026 | 219,301 |
| LEVINE MARK S | Officer | Sale | Nov 19, 2024 | 319,228 |
| MACIAS WILLIAM L | Officer | Sale | Feb 18, 2025 | 357,353 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 7.84% | 16,186,469 | 459.86M | Jun 29, 2026 |
| Deep Track Capital, Lp | 4.52% | 9,341,151 | 265.38M | Jun 29, 2026 |
| Blackrock Inc. | 3.48% | 7,180,897 | 204.01M | Jun 29, 2026 |
| Farallon Capital Management LLC | 2.81% | 5,805,000 | 164.92M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 2.63% | 5,435,220 | 154.41M | Jun 29, 2026 |
| State Street Corporation | 2.24% | 4,617,005 | 131.17M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.47% | 5,092,337 | 144.67M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.26% | 2,600,086 | 73.87M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.09% | 2,251,148 | 63.96M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.02% | 2,107,163 | 59.86M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.91% | 1,881,798 | 53.46M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.68% | 1,408,872 | 40.03M | Aug 30, 2026 |